Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:0
|
作者
Georgios Kontorinis
Jaya Nichani
Simon R. Freeman
Scott A. Rutherford
Samantha Mills
Andrew T. King
Deborah Mawman
Sue Huson
Martin O’Driscoll
D. Gareth Evans
Simon K. W. Lloyd
机构
[1] Central Manchester University Hospitals NHS Foundation Trust,University Department of Otolaryngology
[2] Salford Royal NHS Foundation Trust,Department of Neurosurgery
[3] Salford Royal NHS Foundation Trust,Department of Neuroradiology
[4] Central Manchester University Hospitals NHS Foundation Trust,Department of Genetics Medicine
[5] University of Manchester,School of Cancer and Enabling Services
[6] Southern Teaching Hospital,Department of Otolaryngology, Institute of Neurosciences
来源
European Archives of Oto-Rhino-Laryngology | 2015年 / 272卷
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8–21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p =  0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7–19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients’ age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:7
相关论文
共 50 条
  • [41] Neurofibromatosis Type 2
    Slattery, William H.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2015, 48 (03) : 443 - +
  • [42] Neurofibromatosis type 2
    Goutagny, S.
    Bouccara, D.
    Bozorg-Grayeli, A.
    Sterkers, O.
    Kalamarides, M.
    REVUE NEUROLOGIQUE, 2007, 163 (8-9) : 765 - 777
  • [43] Impact of cochlear implantation on the management strategy of patients with neurofibromatosis type 2
    Haoyue Tan
    Huan Jia
    Yun Li
    Zhihua Zhang
    Weidong Zhu
    Yun Cai
    Zhaoyan Wang
    Hao WU
    European Archives of Oto-Rhino-Laryngology, 2018, 275 : 2667 - 2674
  • [44] Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage
    Sponghini, Andrea P.
    Platini, Francesca
    Rondonotti, David
    Soffietti, Riccardo
    TUMORI, 2015, 101 (06) : E167 - E170
  • [45] Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities
    Sverak, Pavlina
    Adams, Meredith E.
    Haines, Stephen J.
    Levine, Samuel C.
    Nascene, David
    Sommer, Katherine
    Dusenbery, Kathryn
    Huang, Tina C.
    Moertel, Christopher
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2019, 160 (03) : 526 - 532
  • [46] Hearing preservation surgery for neurofibromatosis type 2-related vestibular schwannoma in pediatric patients
    Slattery, William H., III
    Fisher, Laurel M.
    Hitselberger, William
    Friedman, Rick A.
    Brackmann, Derald E.
    JOURNAL OF NEUROSURGERY, 2007, 106 (04) : 255 - 260
  • [47] Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2
    Huang, Victoria
    Bergner, Amanda L.
    Halpin, Chris
    Merker, Vanessa L.
    Sheridan, Monica R.
    Widemann, Brigitte C.
    Blakeley, Jaishri O.
    Plotkin, Scott R.
    OTOLOGY & NEUROTOLOGY, 2018, 39 (05) : 632 - 638
  • [48] Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation
    Screnci, Melina
    Puechmaille, Mathilde
    Berton, Quentin
    Khalil, Toufic
    Mom, Thierry
    Coll, Guillaume
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (23)
  • [49] Impact of cochlear implantation on the management strategy of patients with neurofibromatosis type 2
    Tan, Haoyue
    Jia, Huan
    Li, Yun
    Zhang, Zhihua
    Zhu, Weidong
    Cai, Yun
    Wang, Zhaoyan
    Wu, Hao
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2018, 275 (11) : 2667 - 2674
  • [50] Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]
    Evans, D. Gareth R.
    GENETICS IN MEDICINE, 2009, 11 (09) : 599 - 610